Reconsidering the Trade-offs of Prostate Cancer Screening

Affiliations

¹ From the Department of Urology, Weill Cornell Medicine, New York (J.E.S., J.C.H.); and the Department of Urology, University of Washington (Y.A.N.), and the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center (Y.A.N., R.G., R.E.) - both in Seattle.

Jonathan E Shoag et al. N Engl J Med. 2020.

. 2020 Jun 18;382(25):2465-2468.

doi: 10.1056/NEJMsb2000250.

¹ From the Department of Urology, Weill Cornell Medicine, New York (J.E.S., J.C.H.); and the Department of Urology, University of Washington (Y.A.N.), and the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center (Y.A.N., R.G., R.E.) - both in Seattle.

No abstract available

Comment in

Reconsidering the Trade-offs of Prostate Cancer Screening.
Wittmann D, Skolarus T, Glodé LM. Wittmann D, et al. N Engl J Med. 2020 Sep 24;383(13):1289-1290. doi: 10.1056/NEJMc2025138. N Engl J Med. 2020. PMID: 32966735 No abstract available.

1. Analysis data. Surveillance, Epidemiology, and End Results Program, National Cancer Institute (https://seer.cancer.gov/seerstat/analysis.html).
1. US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 2018; 319:1 901–13.
1. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;1 57: 120–34. - PubMed
1. Lee DJ, Mallin K, Graves AJ, et al. Recent changes in prostate cancer screening practices and epidemiology. J Urol 2017; 198: 1230–40. - PubMed
1. Welch HG, Kramer BS, Black WC. Epidemiologic signatures in cancer. N Engl J Med 2019; 381: 1378–86. - PubMed